[Bone destruction and bone loss in rheumatoid arthritis--mechanism, prevention and treatment].
Suzuki
Yasuo
Y
Department of Rheumatic and Allergic Diseases, St. Marianna University School of Medicine.
Ide
Mikako
M
Uehara
Ritsuko
R
Itoh
Gen
G
D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy; D015519:Bone Density; D001862:Bone Resorption; D002136:Calcium, Dietary / Q000008:administration & dosage; D002762:Cholecalciferol / Q000627:therapeutic use; D016207:Cytokines / Q000502:physiology; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D010010:Osteoclasts / Q000166:cytology / Q000502:physiology; D010024:Osteoporosis / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor; D013583:Synovial Membrane / Q000166:cytology
D002136:Calcium, Dietary; D016207:Cytokines; D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human; D002762:Cholecalciferol; D008727:Methotrexate